Cognitive behavioral telehealth treatment for adolescents with loss-of-control eating: A randomized controlled feasibility study.

Psychotherapy (Chic)May 7, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Janet A Lydecker, Rebecca Kamody, Elise Ozbardakci et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the feasibility and acceptability of a telehealth cognitive behavioral therapy (CBT) intervention for adolescents aged 12-17 with loss-of-control (LOC) eating. Among 50 participants, CBT-LOC showed significant improvements in binge eating, LOC eating, and eating-disorder psychopathology compared to nutrition education, with high retention and treatment satisfaction rates. Notably, treatment satisfaction was higher in the CBT-LOC group (p < .001).

Key findings

  • Retention rate was high, with an average of 15.3 out of 16 sessions completed.
  • CBT-LOC resulted in greater improvements in binge eating and LOC eating compared to nutrition education.
  • Treatment satisfaction was significantly higher in the CBT-LOC group than in the nutrition education group (p < .001).
  • Minimal weight change was observed in both intervention groups.

Why it matters

The study highlights the potential of telehealth CBT for addressing LOC eating in adolescents, a condition that can significantly impact mental health and well-being. Understanding its feasibility and acceptability can inform future treatment approaches in this population.

Source

Published in Psychotherapy (Chic). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.